Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) Non Operating Income (2020 - 2025)

Candel Therapeutics' Non Operating Income history spans 4 years, with the latest figure at -$777000.0 for Q4 2023.

  • On a quarterly basis, Non Operating Income fell 125.75% to -$777000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was -$374000.0, a 102.35% decrease, with the full-year FY2025 number at $89000.0, up 100.41% from a year prior.
  • Non Operating Income hit -$777000.0 in Q4 2023 for Candel Therapeutics, down from $426000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for CADL hit a ceiling of $9.3 million in Q4 2021 and a floor of -$11.8 million in Q2 2021.
  • Historically, Non Operating Income has averaged $897200.0 across 4 years, with a median of $154000.0 in 2020.
  • The widest YoY moves for Non Operating Income: up 6521.28% in 2021, down 4483.27% in 2021.
  • Tracing CADL's Non Operating Income over 4 years: stood at $141000.0 in 2020, then surged by 6521.28% to $9.3 million in 2021, then plummeted by 67.67% to $3.0 million in 2022, then plummeted by 125.75% to -$777000.0 in 2023.
  • Business Quant data shows Non Operating Income for CADL at -$777000.0 in Q4 2023, $426000.0 in Q3 2023, and -$35000.0 in Q2 2023.